Floatz logo

435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Alintegimod
Melanoma
7 Hills Pharma, LLCP1/2CC (41)
Amt-116 Car-T Cells
Melanoma
Beijing Immunochina Medical Science & Technology Co., Ltd.P1/2CC (41)
Amt-253 Car-T Cells
Melanoma
Beijing Immunochina Medical Science & Technology Co., Ltd.P1/2CC (41)
Amxt1501
Melanoma
Aminex Therapeutics, Inc.P1/2CC (41)
Anti-Hcd70 Car Transduced Pbl
Melanoma
National Cancer Institute (NCI)P1/2CC (41)
azd6750
Melanoma
AstraZenecaP1/2CC (41)
Bgb-A445
Melanoma
BeiGeneP1/2CC (41)
bi-1808
Melanoma
BioInvent International ABP1/2CC (41)
Bms-936558-01
Melanoma
Bristol-Myers SquibbP1/2CC (41)
Cba-1205
Melanoma
Chiome Bioscience Inc.P1CC (41)
Cjrb-101
Melanoma
CJ Bioscience, Inc.P1/2CC (41)
CRX100
Melanoma
BioEclipse TherapeuticsP1CC (41)
Ctx-8371
Melanoma
Compass TherapeuticsP1CC (41)
Dapansutrile
Melanoma
April Salama, M.D.P1/2CC (41)
DLL3 CAR-T cells
Melanoma
Shenzhen Geno-Immune Medical InstituteP1/2CC (41)
Eflornithine
Melanoma
Aminex Therapeutics, Inc.P1/2CC (41)
Fosdesdenosine Sipalabenamide
Melanoma
NuCana plcP1/2CC (41)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Melanoma
Cancer Research UKP1/2CC (41)
GD2-SADA
Melanoma
Y-mAbs TherapeuticsP1CC (41)
gen1042
Melanoma
GenmabP1/2CC (41)
hx009
Melanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.P1/2CC (41)
Ifebemtinib
Melanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.P1/2CC (41)
ik-595
Melanoma
Ikena OncologyP1CC (41)
ilb2109
Melanoma
Innolake BiopharmP1/2CC (41)
imm60
Melanoma
iOx TherapeuticsP1/2CC (41)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Ba3071 ?1-Chain), Disulfide With Human Monoclonal Ba3071 ?-Chain, Dimer
Melanoma
BioAtla, Inc.P1/2CC (41)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Cc Chemokine Receptor Ccr8) (Human-Mus Musculus Monoclonal Bms-986340 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Bms-986340 ?-Chain, Dimer
Melanoma
Bristol-Myers SquibbP1/2CC (41)
Inbrx-106
Melanoma
Inhibrx Biosciences, IncP1/2CC (41)
Interleukin 18 (Recombinant Human Mutein Clone St-067)
Melanoma
Simcha IL-18, Inc.P1/2CC (41)
Inupadenant
Melanoma
iTeos Belgium SAP1/2CC (41)
ipn01194
Melanoma
IpsenP1/2CC (41)
jk08
Melanoma
Salubris Biotherapeutics IncP1/2CC (41)
kd6001
Melanoma
Shanghai Kanda Biotechnology Co., Ltd.P1/2CC (41)
Ksq-001Ex
Melanoma
M.D. Anderson Cancer CenterP1/2CC (41)
n17350
Melanoma
Onchilles Pharma IncP1/2CC (41)
neo212
Melanoma
Neonc Technologies, Inc.P1/2CC (41)
ngm707
Melanoma
NGM Biopharmaceuticals, IncP1/2CC (41)
Pexmetinib
Melanoma
Dan ZandbergP1/2CC (41)
pf-08046031
Melanoma
PfizerP1CC (41)
pf-08046037
Melanoma
PfizerP1CC (41)
Phase 1A: Lb-Lr1109
Melanoma
LG ChemP1CC (41)
prj1-3024
Melanoma
Zhuhai Yufan Biotechnologies Co., LtdP1/2CC (41)
Pumitamig
Melanoma
Bristol-Myers SquibbP1/2CC (41)
Recombinant Fully Human Igg1 Kappa Anti-Tigit Monoclonal Antibody Eos-448
Melanoma
iTeos Belgium SAP1/2CC (41)
Regn10597
Melanoma
Regeneron PharmaceuticalsP1/2CC (41)
Rilvegostomig
Melanoma
AstraZenecaP1/2CC (41)
Solnerstotug
Melanoma
Sensei Biotherapeutics, Inc.P1/2CC (41)
<Sup>177</Sup>Lu-Dota
Melanoma
Y-mAbs TherapeuticsP1CC (41)
SX682
Melanoma
Syntrix Biosystems, Inc.P1CC (41)
Tarlatamab
Melanoma
University of ArizonaP1/2CC (41)
Showing 251 to 300 of 435 assets
PreviousPage 6 of 9Next